No­var­tis makes its case on why RTH258 can grab a block­buster piece of Re­gen­eron's AMD mar­ket

Soon-to-be No­var­tis $NVS CEO Vas Narasimhan has peeled back the cov­er on more de­tailed Phase III da­ta for their block­buster Eylea ri­val RTH258 (brolu­cizum­ab), ex­plain­ing why he be­lieves the phar­ma gi­ant has a new drug for wet age-re­lat­ed mac­u­lar de­gen­er­a­tion that has proven to be con­sid­er­ably bet­ter than Re­gen­eron’s $5 bil­lion fran­chise ther­a­py Eylea. But he has one oth­er hur­dle to clear be­fore mak­ing a slight­ly paused ar­rival at the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER